Canada Pension Plan Investment Board increased its position in shares of Novavax, Inc. (NASDAQ:NVAX) by 287.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 474,900 shares of the biopharmaceutical company’s stock after buying an additional 352,400 shares during the period. Canada Pension Plan Investment Board owned about 0.17% of Novavax worth $546,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVAX. HighTower Advisors LLC increased its position in Novavax by 3.8% in the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 5,250 shares during the last quarter. American International Group Inc. increased its position in Novavax by 7.1% in the first quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 10,965 shares during the last quarter. KCG Holdings Inc. increased its position in Novavax by 161.0% in the first quarter. KCG Holdings Inc. now owns 178,797 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 110,292 shares during the last quarter. Wells Fargo & Company MN increased its position in Novavax by 2.7% in the first quarter. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company’s stock valued at $440,000 after buying an additional 8,966 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Novavax during the fourth quarter valued at $544,000. Institutional investors own 45.16% of the company’s stock.

Shares of Novavax, Inc. (NASDAQ NVAX) opened at 1.06 on Thursday. The stock’s market cap is $307.29 million. The stock has a 50 day moving average of $1.11 and a 200 day moving average of $1.13. Novavax, Inc. has a one year low of $0.73 and a one year high of $8.49.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). The business had revenue of $6.70 million during the quarter, compared to the consensus estimate of $6.15 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The company’s quarterly revenue was up 168.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.29) earnings per share. On average, analysts forecast that Novavax, Inc. will post ($0.62) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Canada Pension Plan Investment Board Boosts Position in Novavax, Inc. (NVAX)” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/canada-pension-plan-investment-board-boosts-position-in-novavax-inc-nvax/1533060.html.

Several research firms have weighed in on NVAX. Zacks Investment Research downgraded shares of Novavax from a “buy” rating to a “hold” rating in a report on Saturday, August 19th. BidaskClub upgraded shares of Novavax from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Ladenburg Thalmann Financial Services upgraded shares of Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price objective on the stock in a report on Wednesday, August 9th. Chardan Capital restated a “neutral” rating and set a $1.50 price objective on shares of Novavax in a report on Thursday, July 27th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $1.50 price objective on shares of Novavax in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. Novavax has a consensus rating of “Hold” and a consensus price target of $2.67.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX).

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.